Our finding that the cancer risk under tofacitinib therapy was higher than under anti-TNF therapy but not for the placebo can be explained by the higher risk of cancer induced by uncontrolled inflammation in patients not being treated with immunosuppressive or biological drugs or by a potential direct antineoplastic effect of anti-TNF agents [15]. The gene discussed is TNF; the disease is cancer.